Merck & Co., Inc. Unit Sues Glenmark Pharmaceuticals for Infringing Patent on Diabetes Drugs
Published: Apr 03, 2013
US-based MSD Pharma, the third-largest pharma company in the world by revenues, has asked the Delhi High Court to bar Mumbai-based Glenmark from selling two popular anti-diabetic drugs, triggering yet another legal battle between an Indian generic company and a member of Big Pharma. MSD's move comes a week after Glenmark Pharma launched generic versions of a range of anti-diabetes products sold by the US company under the brand names Januvia and Janumet. Glenmark has branded its medicines Zita and Zita Met and aims to grab a share of the 3,000-crore Indian anti-diabetic market. MSD's drug costs 40 per tablet. Glenmark officials, who did not wish to go on record, said it has priced its product at a 20% discount to the innovator's version.